Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RC148 + telisotuzumab adizutecan
- Development stage
- Phase 2
- Lead developer
- RemeGen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
RC148 + Temab-A is an investigational combination therapy consisting of RC148 (ABBV-1480), a novel bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor A (VEGF-A), and Temab-A (telisotuzumab adizutecan; ABBV-400), a c-Met-directed antibody-drug conjugate (ADC) carrying a topoisomerase 1 inhibitor payload (adizutecan). This combination pairs immune checkpoint inhibition and anti-angiogenic activity with targeted cytotoxic activity. It is being developed by RemeGen and AbbVie for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC) and colorectal cancer (CRC).
- Other names
- ABBV-1480 + ABBV-400ABBV-1480 + telisotuzumab adizutecanRC148 + ABBV-400RC148 + Temab-Atelisotuzumab adizutecan + ABBV-1480telisotuzumab adizutecan + RC148
02
Targets
MET (Mesenchymal-epithelial transition factor receptor)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on RC148 + telisotuzumab adizutecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RC148 + telisotuzumab adizutecan.